SEELOS THERAPEUTICS INC (SEEL)

US81577F3073 - Common Stock

0.9069  -0.05 (-5.53%)

After market: 0.9438 +0.04 (+4.07%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SEELOS THERAPEUTICS INC

NASDAQ:SEEL (6/14/2024, 7:00:01 PM)

After market: 0.9438 +0.04 (+4.07%)

0.9069

-0.05 (-5.53%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-92.73%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.37M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SEEL Daily chart

Company Profile

Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 16 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing programs include SLS-004, SLS-006, and SLS-007.

Company Info

SEELOS THERAPEUTICS INC

300 Park Avenue, 2nd Floor

New York City NEW YORK 10022

P: 16462932100

CEO: Raj Mehra

Employees: 16

Website: https://seelostherapeutics.com/

SEEL News

News Imagea month ago - Seelos Therapeutics, Inc.Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

News Imagea month ago - InvestorPlaceSEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024

SEEL stock results show that Seelos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Imagea month ago - Seelos Therapeutics, Inc.Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

News Image2 months ago - Seelos Therapeutics, Inc.Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

News Image2 months ago - InvestorPlaceToday‚Äôs Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!

News Image3 months ago - InvestorPlaceSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023

SEEL stock results show that Seelos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

SEEL Twits

Here you can normally see the latest stock twits on SEEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example